		Lasti	name		Firstname		
NYU HOSPIT	TALS CENTER	Ν	1RN		Sex	DOB	
PRE-PROCED	URE		aat		D		
	PTIMIZATION F		ССТ		Pt Type		
	INVITZATION	ORW					
Page <b>1</b> of <b>3</b>							
Section 1: To Be Com	pleted By the Physici	an Performing the Procedure	Sle	ep Apnea Scr	reen (High Ris	$k \ge 3$ Items)	
	<u>.</u>			<u>S</u> noring		ouder than talking or loud	
Procedure-Related	Diagnosis:			Tingd	enough to be heard thro	•	
Proposed Procedur	ra.			<u><b>T</b></u> ired	Do you often feel tired, during daytime?	fatigued, or sleepy	
1 loposed 1 locedul				<u>O</u> bserved		ou stop breathing during	
Date of Procedure:			_		Observed Has anyone observed you stop breathing during your sleep?		
				<b>P</b> ressure	Pressure Do you have or are you being treated for high		
PAT Date (if Sche	duled):				blood pressure?		
D. 17. /				<u><b>B</b></u> MI	BMI more than 35 kg/n	n <sup>2</sup> ?	
Proposed Location		20 <sup>th</sup> Street		<u>A</u> ge	Age over 50 years old? Neck circumference greater than 40 cm?		
□ Tisch Campus □ HJD Campus		38 <sup>th</sup> Street Other:		<u>N</u> eck <u>G</u> ender	Seck circumference gree Gender male or post-me		
÷				Gendel	Sender mule of post-mo	enopuusui temute:	
Section 2: To Be Comp	pleted By Consulting	Physician				Past Surgical Hx:	
Does the Patient h	have Any of the	Following Conditions?					
	-	nts unrelated to the "Procedure-Re	lated	Diagnosis"			
	If Yes, describe:						
$\Box$ No $\Box$ Yes	<b>Cardiac Stent:</b> Drug Eluting Dare Metal If "Yes" to either, see last page of the						
□ No □ Yes	DVT/PE:	form regarding management of antiplatelet therapy					
· · · · · · · · · · · · · · · · · · ·	HTN:	Date:       □ Currently anticoagulated       □ IVC Filter         Controlled?       □ Yes       □ No					
	DM:	Controlled? $\Box$ Yes $\Box$ No $\Box$ Insulin A1c: Date:					
		Microvascular complications:					
□ No □ Yes	ASHD/CAD:	□ CABG □ Stent □ Prior MI_LVEF:					
-	CHF:	Diastolic Systolic LVE		Last Exac	Date:		
		Last Diuretic Dose Change: Date:					
	OSAS/OHS:	$\Box$ on PAP Rx at home EPAP:/ IPAP:cm H <sub>2</sub> O					
$\Box$ No $\Box$ Yes	COPD/Asthma:	Controlled?   Yes   No Las			Date:		
	4 013	Last Exac: Home					
$\Box$ No $\Box$ Yes	Afib:	$\Box$ Chronic $\Box$ Paroxysmal $\Box$ (			nt:		
	Current rhythm: If SR, date last fib:						
	CKD: ICD:	Stable? □ Yes □ No Cr:       Date:         Indication:       Date implanted :					
	ICD,	Mfr: Last interrogate	d.				
□ No □ Yes	PPM:	Indication:	Dat	e implanted ·		Details and Addnl	
		Indication: Mfr: Last interrogate	d:	- inprantou .		Past Med Hx:	
□ No □ Yes	RA/Other Rheum:	□ On biologic Rx □ On chron	ic coi	ticosteroid (I	Dose:)		
□ No □ Yes	Hepatitis C+:	□ On Treatment □ Completed Treatment □ Never Treated					
	HIV+	Year Dx:         CD4:         VL:         Date:         □ HAART           Cause:         Alb:         AST/ALT:         Bili:         INR:					
$\Box$ No $\Box$ Yes	Cirrhosis:	Cause: Alb: A	ST/A	ALT:Bil	i: INR:		
		AlkP:					
	GI Bleed:	$\Box$ Upper $\Box$ Lower $\Box$ Re-	1 Tra				
	EtOH Use:	Specify:		⊔ At Risk f	or Post Op W/D		
	Tobacco use: Rec Drugs:	Specify:Specify:		□ At Diale f	or Post Op W/D		
		<u>ollowing Studies/Procedures wit</u>	hin t <sup>i</sup>				
IF YES, SUBMIT				ne past 2 yta	10.		
	Cardiac Catheter		es	PFT			
	Echocardiogram			CXR			
	Stress Test			CT Scan			
	EKG		•••••	MRI			

## NYU HOSPITALS CENTER

PRE-PROCEDURE MEDICAL OPTIMIZATION FORM Page 2 of 3

1 460 2 01 0										
ALLERGIES:	NKDA			I						
Medications: (Include Herbals, Supplements, Alternative Treatments)										
Medications: (Incl Name	Dose	Sals, Sup Freq	plements, Alterr Last Taken	Date to Stop	Naı	<b>m</b> o	Dose	Frog	Last Taken	Data to Stop
Iname	Dose	rieq			Inal		Dose	Freq		Date to Stop
Physical Exam:	BP:		HR:	RR:	T	: SpO2	:		Ht:	Wt:
Gen: HEENT:					GU: Lymp	<u></u>				•••••••
NECK:				•	Msk:	<u>11.</u>				
CV:				•	Skin:					
Pulm:					Neuro	):				•
GI:				Ι	Psych	:				
Additional Physical Exam Comments:								•		
DATA REVIEW	/ <b>:</b>			Describe	pertir	nent abnormal lab	values a	and othe	r/additional relev	ant imaging:
Lab reports end										
Labs are pendi										
Please forward copies of PAT Labs to me										
Revised Cardiac Risk Index								( 10/ <10/		
High Risk Surgery (e.g. vascular, peritoneal, thoracic)						0 risk factors - 0.4% - 1% vs <1% ngina, need for nitrates, w/ beta-blocker				
□ History of Ischemic Heart Disease (e.g. MI, pos. stress, active an, pathologic q on EKG, do not count prior PCI/CABG without other cr										
<ul> <li>History of Heart Failure</li> </ul>					<i>er en</i>	0.8% - 1.6% w/ beta-blocker				
<ul> <li>History of real range</li> <li>History of cerebrovascular disease</li> </ul>						3 +  risk factors - >9%  vs >3%  w/				
<ul> <li>Diabetes mellitus requiring treatment with insulin</li> </ul>						beta-blocker				
Impression:					]	Impression:				
□ The patient IS						<b>The patient</b>				
MAY PROCEED to the operating room as scheduled						□ Has had cardiac BMS within last 6 weeks or DES				
□ Without further assessment.						within 12 months.				
							Needs further optimization e.g. control of asthma,			
	Pending review of other study/evaluation (specify): blood pressure or diabetes (specify):									
Please make <b>specific</b> peri-operative recommendations:										
						□ Needs further diagnostic testing (specify):				
						······································				
	0.1.1					□ Other:				
□ Check here if you feel that for reasons documented above cardiac risk is so significant surgery should be performed at the Tisch Campus.					sk					
Form Completed by:										
I orm Completed by	•									
										AM/PM
Printed Name			Title	Teleph	one	Signature			Date / T	Time

## NYU HOSPITALS CENTER

PRE-PROCEDURE MEDICAL OPTIMIZATION FORM Page **3** of **3** 

## NYU Langone Medical Center Clinical Guideline Summary

Management of antiplatelet therapy, patients s/p PCI, undergoing surgery/invasive procedure

For patients status post percutaneous coronary intervention (PCI) who need non-cardiac invasive procedures, optimal outcomes require careful balance of bleeding risk of continuing anti-platelet therapy against risk of thrombosis and acute myocardial infarction. BEFORE procedure is scheduled, agreement and clarity about anti-platelet therapy management must be achieved through a discussion between the procedure physician (who best understands the bleeding risk) and the cardiologist (who best understands the risk of thrombosis and acute myocardial infarction). JOINT DECISION-MAKING MUST BE DOCUMENTED IN THE MEDICAL RECORD. FAILURE TO DOCUMENT ANTI-PLATELET THERAPY DECISION-MAKING WILL RESULT IN PROCEDURE CANCELLATION.

For major procedures, all patients must be followed while in hospital by an NYULMC cardiologist. If the patient's usual cardiologist is not affiliated with NYULMC, preoperative consultation must be obtained prior to scheduled procedure with an NYULMC cardiologist who will follow the patient during admission.

In addition, patients scheduled to undergo an inpatient procedure at HJD will be evaluated preoperatively by a hospital-based intensivist or NYU cardiologist, for consideration of performing the procedure at Tisch Hospital.

This form may be used to document decision-making. Please fax to PST,

Patient name:	MRN:
Procedure:	Date scheduled:
Procedure physician:	Cardiologist:

	Usual dose	NYULMC guideline	Recommendation of procedure physician
		recommendation	and cardiologist
Aspirin	mg daily □ No aspirin	Continue, unless very high bleeding risk. If aspirin must be stopped, stop 3 days prior to procedure.	<ul> <li>Continue aspirin throughout the perioperative period at a dose of mg daily</li> <li>Stop aspirin on / / (mm/dd/yy).</li> </ul>
<ul> <li>Clopidogrel (Plavix®)</li> <li>Prasugrel (Efient®)</li> <li>Ticagrelor (Brilinte®)</li> </ul>	mg daily mg twice daily	Continue, unless high bleeding risk. If thienopyridine must be stopped, stop $3 - 5$ days prior to procedure.	<ul> <li>Continue thienopyridine throughout the perioperative period at a dose of  mg daily or mg twice daily</li> <li>Stop thienopyridine on / / (mm/dd/yy).</li> </ul>
(thienopyridines)	□ No thienopyridine		